Chiauranib
- Generic Name
- Chiauranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H21N3O3
- CAS Number
- 1256349-48-0
- Unique Ingredient Identifier
- F40IRN5981
- Background
Chiauranib is under investigation in clinical trial NCT03974243 (Chiauranib in Combination With Chidamide in Patients With Relapsed/refractory Non-hodgkin's Lymphoma).
- Indication
用于治疗经过2线系统化疗方案后疾病进展或复发的小细胞肺癌（SCLC）。
- Associated Conditions
- -
- Associated Therapies
- -
The Phase III clinical trial application for first-line treatment of extensive disease small cell
Chipscreen Biosciences' Chiauranib, combined with PD-(L)1 and chemotherapy, approved for Phase III trials in first-line treatment of extensive stage small cell lung cancer. Chiauranib's multi-pathway mechanism enhances chemo-immunotherapy, potentially improving long-term survival.
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer
Chipscreen Biosciences' Chiauranib, combined with PD-(L)1 and chemotherapy, approved for phase III trials in first-line treatment of extensive stage small cell lung cancer, aiming to improve long-term survival.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath